Ardelyx
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 267
- Market Cap
- $1.4B
- Website
- http://www.ardelyx.com
- Introduction
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 71
- Registration Number
- NCT02140281
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 65
- Registration Number
- NCT02140268
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Dose Finding Study to Treat High Phosphate Levels in the Blood.
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 162
- Registration Number
- NCT02081534
- Locations
- 🇬🇧
Research Site, London, United Kingdom
AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 26
- Registration Number
- NCT02063386
- Locations
- 🇬🇧
Research Site, London, United Kingdom
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
- Conditions
- Interventions
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 356
- Registration Number
- NCT01923428
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
- Conditions
- Interventions
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 154
- Registration Number
- NCT01847092
- Locations
- 🇺🇸
Creekside Endocrine Associates PC, Denver, Colorado, United States
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 88
- Registration Number
- NCT01764854
- Locations
- 🇺🇸
Denver Nephrology, Denver, Colorado, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Southwest Clinical Research Institute, Tempe, Arizona, United States
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
- Conditions
- Interventions
- First Posted Date
- 2011-04-22
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 186
- Registration Number
- NCT01340053
- Locations
- 🇺🇸
Ardelyx Investigational Site, Lynchburg, Virginia, United States